1. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
- Author
-
Gregory P. Forlenza, Timothy Vigers, Laurel H. Messer, Kimberly A. Driscoll, Laura Pyle, Cari Berget, and Erin Cobry
- Subjects
Blood Glucose ,Male ,Insulin pump ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,MEDLINE ,030209 endocrinology & metabolism ,Glycemic Control ,03 medical and health sciences ,Insulin Infusion Systems ,0302 clinical medicine ,Endocrinology ,Diabetes mellitus ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,030212 general & internal medicine ,Glycemic ,Glycated Hemoglobin ,Type 1 diabetes ,business.industry ,Blood Glucose Self-Monitoring ,Original Articles ,medicine.disease ,Pediatric clinic ,Medical Laboratory Technology ,Diabetes Mellitus, Type 1 ,Female ,business ,Closed loop - Abstract
Objective: To describe real-world outcomes for youth using the Tandem t:slim X2 insulin pump with Control-IQ technology (“Control-IQ”) for 6 months at a large pediatric clinic. Methods: Youth with type 1 diabetes, who started Control-IQ for routine care, were prospectively followed. Data on system use and glycemic control were collected before Control-IQ start, and at 1, 3, and 6 months after start. Mixed models assessed change across time; interactions with baseline hemoglobin A1c (HbA1c) and age were tested. Results: In 191 youth (median age 14, 47% female, and median HbA1c 7.6%), percent time with glucose levels 70–180 mg/dL (time-in-range [TIR]) improved from 57% at baseline to 66% at 6 months (P 70%) doubled from 23.5% at baseline to 47.8% at 3 months, sustaining at 46.7% at 6 months (P
- Published
- 2021
- Full Text
- View/download PDF